JUBLPHARMA - Technical Analysis with Chart Patterns & Indicators
Back to ListTechnical Rating: 3.3
| Stock Code | JUBLPHARMA | Market Cap | 13,580 Cr. | Current Price | 851 ₹ | High / Low | 1,250 ₹ |
| Book Value | 141 ₹ | Dividend Yield | 0.58 % | ROCE | 2.91 % | ROE | 1.04 % |
| Face Value | 1.00 ₹ | DMA 50 | 916 ₹ | DMA 200 | 1,009 ₹ | Chg in FII Hold | -0.60 % |
| Chg in DII Hold | 0.70 % | PAT Qtr | 6.60 Cr. | PAT Prev Qtr | -48.0 Cr. | RSI | 45.4 |
| MACD | -26.8 | Volume | 84,305 | Avg Vol 1Wk | 1,81,761 | Low price | 784 ₹ |
| High price | 1,250 ₹ | Debt to equity | 0.02 | 52w Index | 14.4 % | Qtr Profit Var | 154 % |
| EPS | 1.23 ₹ | Industry PE | 27.6 |
📉 Chart & Trend: JUBLPHARMA is trading below both its 50 DMA (₹916) and 200 DMA (₹1009), with the current price at ₹851. This indicates short-term weakness and medium-term bearish consolidation.
📊 RSI: At 45.4, RSI is weak, suggesting limited upside potential and mild bearish bias.
📉 MACD: Negative at -26.8, confirming bearish momentum and lack of reversal signals.
📈 Bollinger Bands: Price is mid-to-lower range, reflecting weakness and potential downside risk if support breaks.
📊 Volume: Current volume (84K) is lower than average weekly volume (181K), showing reduced participation and weak buying interest.
📍 Support & Resistance:
- Strong support: ₹784
- Immediate resistance: ₹916 (50 DMA)
- Major resistance: ₹1009 (200 DMA)
Optimal entry zone: ₹830–₹860 (near support).
Exit zone: ₹900–₹940 (resistance cluster).
🔎 Trend Status: The stock is consolidating with bearish bias. A reversal requires sustained close above ₹916–₹1009.
Positive
- Debt-to-equity ratio of 0.02 indicates minimal leverage risk.
- EPS at ₹1.23 supports earnings visibility despite weak profitability.
- Dividend yield of 0.58% provides modest income support.
- PAT improved to ₹6.6 Cr from -₹48 Cr, showing operational recovery.
- DII holding increased by 0.70%, reflecting domestic institutional support.
Limitation
- Trading below both 50 DMA and 200 DMA signals weakness.
- RSI and MACD confirm bearish momentum.
- ROCE (2.91%) and ROE (1.04%) are very weak compared to sector peers.
- Volume participation is lower than average, limiting breakout strength.
Company Negative News
- PAT remains low at ₹6.6 Cr despite recovery, showing earnings pressure.
- FII holding decreased by -0.60%, reflecting reduced foreign investor confidence.
Company Positive News
- Quarterly profit variation of 154% indicates strong turnaround momentum.
- DII holding increased by 0.70%, showing domestic institutional confidence.
Industry
- Industry PE at 27.6 vs JUBLPHARMA’s undefined P/E highlights valuation uncertainty.
- Pharmaceutical sector outlook remains positive with demand growth in generics and specialty drugs.
Conclusion
⚖️ JUBLPHARMA is consolidating with bearish bias near support. Short-term traders may consider entry around ₹830–₹860 with exits near ₹900–₹940. Long-term investors should be cautious given weak ROE/ROCE and earnings volatility, waiting for confirmation above ₹916–₹1009 before adding positions.
Would you like me to extend this into a pharma sector basket overlay (JUBLPHARMA vs peers like Sun Pharma, Cipla, Dr. Reddy’s) so you can benchmark its setup against industry leaders for stronger confirmation signals?